- Home
- IBRX vs NTB Comparison
IBRX vs NTB Comparison
Compare IBRX & NTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- NTB
- Stock Information
- Founded
- IBRX 2014
- NTB 1858
- Country
- IBRX United States
- NTB Bermuda
- Employees
- IBRX N/A
- NTB N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- NTB Commercial Banks
- Sector
- IBRX Health Care
- NTB Finance
- Exchange
- IBRX Nasdaq
- NTB Nasdaq
- Market Cap
- IBRX 1.9B
- NTB 1.8B
- IPO Year
- IBRX N/A
- NTB 2016
- Fundamental
- Price
- IBRX $3.42
- NTB $38.53
- Analyst Decision
- IBRX Strong Buy
- NTB Buy
- Analyst Count
- IBRX 3
- NTB 7
- Target Price
- IBRX $13.58
- NTB $41.00
- AVG Volume (30 Days)
- IBRX 6.0M
- NTB 180.0K
- Earning Date
- IBRX 03-18-2025
- NTB 02-10-2025
- Dividend Yield
- IBRX N/A
- NTB 4.57%
- EPS Growth
- IBRX N/A
- NTB 2.84
- EPS
- IBRX N/A
- NTB 4.71
- Revenue
- IBRX $7,332,000.00
- NTB $579,933,000.00
- Revenue This Year
- IBRX $2,359.81
- NTB N/A
- Revenue Next Year
- IBRX $808.10
- NTB $1.28
- P/E Ratio
- IBRX N/A
- NTB $8.18
- Revenue Growth
- IBRX 1218.71
- NTB 0.23
- 52 Week Low
- IBRX $2.28
- NTB $29.06
- 52 Week High
- IBRX $10.53
- NTB $41.88
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- NTB 51.00
- Support Level
- IBRX $3.35
- NTB $38.75
- Resistance Level
- IBRX $4.27
- NTB $40.93
- Average True Range (ATR)
- IBRX 0.31
- NTB 1.14
- MACD
- IBRX 0.04
- NTB 0.03
- Stochastic Oscillator
- IBRX 29.17
- NTB 44.54
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, the Cayman Islands, the Channel Islands, and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.